Palliative care and end of life management in patients with idiopathic pulmonary fibrosis.
End of life
health-related quality of life
idiopathic pulmonary fibrosis
palliative care
Journal
Multidisciplinary respiratory medicine
ISSN: 1828-695X
Titre abrégé: Multidiscip Respir Med
Pays: Italy
ID NLM: 101477642
Informations de publication
Date de publication:
17 Jan 2023
17 Jan 2023
Historique:
received:
15
11
2022
accepted:
25
01
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a chronic disease with an unknown etiology that causes deterioration of the structure of the lung parenchyma, resulting in a severe and progressive decline in respiratory function and early mortality. IPF is essentially an incurable disease, with a mean overall survival of 5 years in approximately 20% of patients without treatment. The combination of a poor prognosis, uncertainty about the disease's progression, and the severity of symptoms has a significant impact on the quality of life of patients and their families. New antifibrotic drugs have been shown to slow disease progression, but their impact on health-related quality of life (HRQoL) has to be proven yet. To date, studies have shown that palliative care can improve symptom management, HRQoL, and end-of-life care (EoL) in patients with IPF, reducing critical events, hospitalization, and health costs. As a result, it is essential for proper health planning and patient management to establish palliative care early and in conjunction with other therapies, beginning with the initial diagnosis of the disease.
Identifiants
pubmed: 36909932
doi: 10.4081/mrm.2023.896
pmc: PMC9994447
doi:
Types de publication
Journal Article
Langues
eng
Pagination
896Informations de copyright
©Copyright: the Author(s).
Références
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Eur Respir Rev. 2016 Sep;25(141):278-86
pubmed: 27581827
Chest. 2015 Feb;147(2):423-429
pubmed: 25187973
BMJ Support Palliat Care. 2021 Mar;11(1):40-44
pubmed: 32527790
Respir Med. 2014 Jul;108(7):955-67
pubmed: 24780718
BMJ. 2003 Jan 25;326(7382):185
pubmed: 12543832
Respir Med. 2014 Jan;108(1):203-10
pubmed: 24332409
J Pain Symptom Manage. 2012 Apr;43(4):771-82
pubmed: 22285287
Ann Ist Super Sanita. 2012;48(3):328-33
pubmed: 23007058
Eur Respir J. 2017 Oct 19;50(4):
pubmed: 29051272
Lung. 2012 Apr;190(2):215-20
pubmed: 22218887
J Thorac Cardiovasc Surg. 2014 Jan;147(1):47-53
pubmed: 23968871
CMAJ. 2011 Jul 12;183(10):1170
pubmed: 21746829
Multidiscip Respir Med. 2020 May 25;15(1):672
pubmed: 32499910
BMC Palliat Care. 2017 Jul 11;17(1):6
pubmed: 28693466
Respir Care. 2013 Apr;58(4):597-600
pubmed: 22781059
Nurs Ethics. 2009 May;16(3):292-302
pubmed: 19372124
BMC Palliat Care. 2016 Oct 12;15(1):85
pubmed: 27729035
Thorax. 2016 Jun;71(6):510-6
pubmed: 26865603
Eur Respir J. 2016 Feb;47(2):597-606
pubmed: 26585424
Eur Respir J. 2001 May;17(5):954-61
pubmed: 11488332
Respir Med. 2016 Feb;111:72-6
pubmed: 26733227
Am J Hosp Palliat Care. 2022 Jun;39(6):641-651
pubmed: 34433294
Rev Bras Enferm. 2016 Jun;69(3):591-601
pubmed: 27355311
Curr Opin Support Palliat Care. 2017 Sep;11(3):141-146
pubmed: 28661900
J Palliat Med. 2010 Dec;13(12):1407-13
pubmed: 21105763
J Palliat Med. 2008 Mar;11(2):204-16
pubmed: 18333735
Lancet. 2022 Feb 26;399(10327):837-884
pubmed: 35114146
Lancet Respir Med. 2017 Dec;5(12):968-980
pubmed: 29033267
Cardiovasc Res. 2020 Jan 1;116(1):12-27
pubmed: 31386104
Ochsner J. 2011 Winter;11(4):348-52
pubmed: 22190887
Eur Respir Rev. 2018 Feb 7;27(147):
pubmed: 29436402
Lancet. 2018 Apr 7;391(10128):1391-1454
pubmed: 29032993
J Adv Nurs. 2018 Jun;74(6):1289-1300
pubmed: 29350780
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Ther Adv Respir Dis. 2017 Mar;11(3):157-169
pubmed: 28134007
Heart Lung. 2010 Jul-Aug;39(4):304-13
pubmed: 20561836
N Engl J Med. 2015 Jun 4;372(23):2185-96
pubmed: 25981908